Overview
Late-breaking Science with DOACs and Implications for Patient Care
The Expert Circle
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Hear from Christian Ruff, MD, MPH on the latest clinical trial data related to DOACs and implications for patient care. This expert perspective provides clinicians with practical insights to apply to their practice. Dr. Ruff discusses the most recent evidence with DOACs across a multitude of disease states, including acute venous thromboembolism in patients with elevated BMI, peripheral artery disease, and COVID-19. Exciting new evidence with the novel factor XIa drug class is also covered.
This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hospitalists and primary care physicians.
The purpose of this activity is to provide learners with a succinct and comprehensive review based on the latest DOAC clinical trial data. Clinicians learn about the most recent DOAC evidence in a multitude of disease states, including acute venous thromboembolism in patients with elevated BMI, peripheral artery disease, and COVID-19. Exciting new evidence with the novel factor XIa drug class is also covered.
Upon completion of this activity, participants will be able to:
• Evaluate the latest clinical trial data on DOACs
• Incorporate DOACs into appropriate prophylaxis and/or treatment plans based on recent evidence
• Evaluate the latest clinical trial data on DOACs
• Incorporate DOACs into appropriate prophylaxis and/or treatment plans based on recent evidence
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
This activity was part of a serial learning curriculum. This functionality is no longer available due to activity expiration.
Christian T. Ruff, MD, MPH
Director, General Cardiology, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Director, General Cardiology, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Christian T. Ruff, MD, MPH
Consultant (Occasional): Anthos, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Alexion (formally Portola)
Grant/Research Support recipient: Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Use of DOACs in patients with elevated BMI, patients with COVID-19, LV thrombus, chronic kidney disease. Discussion of investigational milvexian.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
